Review ArticleReview

Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

Meng Zhang, Ergang Liu, Yanna Cui and Yongzhuo Huang
Cancer Biology & Medicine August 2017, 14 (3) 212-227; DOI: https://doi.org/10.20892/j.issn.2095-3941.2017.0054

References

  1. 1.↵
    2. Ferlay J,
    3. Soerjomataram I,
    4. Dikshit R,
    5. Eser S,
    6. Mathers C,
    7. Rebelo M, et al.
    Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359–86.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Fell JW.
    A treatise on cancer, and its treatment. London: J. Churchill, 1857.
  3. 3.↵
    2. Walshe WH.
    The nature and treatment of cancer. London: Taylor and Walton, 1846.
  4. 4.↵
    2. Kunjachan S,
    3. Rychlik B,
    4. Storm G,
    5. Kiessling F,
    6. Lammers T.
    Multidrug resistance: physiological principles and nanomedical solutions. Adv Drug Deliv Rev. 2013; 65: 1852–65.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Tsuruo T,
    3. Naito M,
    4. Tomida A,
    5. Fujita N,
    6. Mashima T,
    7. Sakamoto H, et al.
    Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003; 94: 15–21.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Yoo CB,
    3. Jones PA.
    Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5: 37–50.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Miller KD,
    3. Siegel RL,
    4. Lin CC,
    5. Mariotto AB,
    6. Kramer JL,
    7. Rowland JH, et al.
    Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66: 271–89.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Zahreddine H,
    3. Borden KLB.
    Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013; 4: 28
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Labi V,
    3. Erlacher M.
    How cell death shapes cancer. Cell Death Dis. 2015; 6: e1675
  10. 10.↵
    2. Holohan C,
    3. Van Schaeybroeck S,
    4. Longley DB,
    5. Johnston PG.
    Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13: 714–26.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    2. Wu Q,
    3. Yang ZP,
    4. Nie YZ,
    5. Shi YQ,
    6. Fan D.
    Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014; 347: 159–66.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. DeSantis CE,
    3. Lin CC,
    4. Mariotto AB,
    5. Siegel RL,
    6. Stein KD,
    7. Kramer JL, et al.
    Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64: 252–71.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Longley DB,
    3. Johnston PG.
    Molecular mechanisms of drug resistance. J Pathol. 2005; 205: 275–92.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. Pan ST,
    3. Li ZL,
    4. He ZX,
    5. Qiu JX,
    6. Zhou SF.
    Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016; 43: 723–37.
    OpenUrl
  15. 15.↵
    2. Kibria G,
    3. Hatakeyama H,
    4. Harashima H.
    Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2014; 37: 4–15.
    OpenUrl
  16. 16.↵
    2. Rebucci M,
    3. Michiels C.
    Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013; 85: 1219–26.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Yap TA,
    3. Omlin A,
    4. de Bono JS.
    Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol. 2013; 31: 1592–605.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Cao P,
    3. Bae Y.
    Polymer nanoparticulate drug delivery and combination cancer therapy. Future Oncol. 2012; 8: 1471–80.
    OpenUrlPubMed
  19. 19.↵
    2. Rempe R,
    3. Cramer S,
    4. Qiao RR,
    5. Galla HJ.
    Strategies to overcome the barrier: use of nanoparticles as carriers and modulators of barrier properties. Cell Tissue Res. 2014; 355: 717–26.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    2. Lee MJ,
    3. Ye AS,
    4. Gardino AK,
    5. Heijink AM,
    6. Sorger PK,
    7. MacBeath G, et al.
    Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 2012; 149: 780–94.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Gao ZB,
    3. Zhang LN,
    4. Sun YJ.
    Nanotechnology applied to overcome tumor drug resistance. J Control Release. 2012; 162: 45–55.
    OpenUrlPubMed
  22. 22.↵
    2. Steichen SD,
    3. Caldorera-Moore M,
    4. Peppas NA.
    A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013; 48: 416–27.
    OpenUrlCrossRef
  23. 23.↵
    2. Liu JH,
    3. Zhao YX,
    4. Guo QQ,
    5. Wang Z,
    6. Wang HY,
    7. Yang YX, et al.
    TAT-modified nanosilver for combating multidrug-resistant cancer. Biomaterials. 2012; 33: 6155–61.
    OpenUrl
  24. 24.↵
    2. Wang HX,
    3. Zhao YX,
    4. Wang HY,
    5. Gong JB,
    6. He HN,
    7. Shin MC, et al.
    Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. J Control Release. 2014; 192: 47–56.
    OpenUrl
  25. 25.↵
    2. Liang JM,
    3. Zeng F,
    4. Zhang M,
    5. Pan ZZ,
    6. Chen YZ,
    7. Zeng YE, et al.
    Green synthesis of hyaluronic acid-based silver nanoparticles and their enhanced delivery to CD44+ cancer cells. RSC Adv. 2015; 5: 43733–40.
    OpenUrl
  26. 26.↵
    2. Daniel DB,
    3. Ramachandran G,
    4. Swaminathan S.
    The challenges of pharmacokinetic variability of first-line anti-TB drugs. Expert Rev Clin Pharmacol. 2017; 10: 47–58.
    OpenUrl
  27. 27.↵
    2. Reynolds J,
    3. Heysell SK.
    Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol. 2014; 10: 813–23.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Ma L,
    3. Kohli M,
    4. Smith A.
    Nanoparticles for combination drug therapy. ACS Nano. 2013; 7: 9518–25.
    OpenUrlCrossRefPubMed
  29. 29.↵
    2. Mayer LD,
    3. Janoff AS.
    Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007; 7: 216–23.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    2. Tardi PG,
    3. Dos Santos N,
    4. Harasym TO,
    5. Johnstone SA,
    6. Zisman N,
    7. Tsang AW, et al.
    Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther. 2009; 8: 2266–75.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    2. Liu YR,
    3. Fang JX,
    4. Kim YJ,
    5. Wong MK,
    6. Wang P.
    Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm. 2014; 11: 1651–61.
    OpenUrl
  32. 32.↵
    2. Chen SH,
    3. Liang QL,
    4. Liu EG,
    5. Yu ZL,
    6. Sun L,
    7. Ye JX, et al.
    Curcumin/sunitinib co-loaded BSA-stabilized SPIOs for synergistic combination therapy for breast cancer. J Mater Chem B. 2017; 5: 4060–72.
    OpenUrl
  33. 33.↵
    2. Wei Z,
    3. Yuan S,
    4. Hao JG,
    5. Fang XL.
    Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity. Eur J Pharm Biopharm. 2013; 83: 266–74.
    OpenUrl
  34. 34.
    2. Li WJ,
    3. Li XR,
    4. Gao YJ,
    5. Zhou YX,
    6. Ma SJ,
    7. Zhao Y, et al.
    Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity. Mol Pharm. 2014; 11: 71–80.
    OpenUrl
  35. 35.↵
    2. Collnot EM,
    3. Baldes C,
    4. Schaefer UF,
    5. Edgar KJ,
    6. Wempe MF,
    7. Lehr CM.
    Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm. 2010; 7: 642–51.
    OpenUrlCrossRefPubMed
  36. 36.↵
    2. Tan GR,
    3. Feng SS,
    4. Leong DT.
    The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. Biomaterials. 2014; 35: 3044–51.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Li PY,
    3. Lai PS,
    4. Hung WC,
    5. Syu WJ.
    Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules. 2010; 11: 2576–82.
    OpenUrlCrossRefPubMed
  38. 38.↵
    2. Riganti C,
    3. Voena C,
    4. Kopecka J,
    5. Corsetto PA,
    6. Montorfano G,
    7. Enrico E, et al.
    Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm. 2011; 8: 683–700.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Liu YR,
    3. Fang JX,
    4. Joo KI,
    5. Wong MK,
    6. Wang P.
    Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor. PLoS One. 2014; 9:e110611
  40. 40.↵
    2. Tsouris V,
    3. Joo MK,
    4. Kim SH,
    5. Kwon IC,
    6. Won YY.
    Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers. Biotechnol Adv. 2014; 32: 1037–50.
    OpenUrlCrossRefPubMed
  41. 41.↵
    2. Song XR,
    3. Cai Z,
    4. Zheng Y,
    5. He G,
    6. Cui FY,
    7. Gong DQ, et al.
    Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci. 2009; 37: 300–5.
    OpenUrlPubMed
  42. 42.↵
    2. Thomas H,
    3. Coley HM.
    Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003; 10: 159–65.
    OpenUrlPubMed
  43. 43.↵
    2. Wang FH,
    3. Zhang DR,
    4. Zhang Q,
    5. Chen YX,
    6. Zheng DD,
    7. Hao LL, et al.
    Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. Biomaterials. 2011; 32: 9444–56.
    OpenUrl
  44. 44.↵
    2. Patil Y,
    3. Sadhukha T,
    4. Ma LN,
    5. Panyam J.
    Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release. 2009; 136: 21–9.
    OpenUrlCrossRefPubMed
  45. 45.↵
    2. Mitrus I,
    3. Sochanik A,
    4. Cichoú T,
    5. Szala S.
    Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochim Pol. 2009; 56: 161–5.
    OpenUrlPubMed
  46. 46.↵
    2. Zhang YF,
    3. Wang JC,
    4. Bian DY,
    5. Zhang X,
    6. Zhang Q.
    Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm. 2010; 74: 467–73.
    OpenUrlCrossRefPubMed
  47. 47.↵
    2. Yang TY,
    3. Wang YG,
    4. Li ZQ,
    5. Dai WB,
    6. Yin J,
    7. Liang L, et al.
    Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine. 2012; 8: 81–92.
    OpenUrlCrossRefPubMed
  48. 48.↵
    2. Wang Z,
    3. Ho PC.
    A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials. 2010; 31: 7115–23.
    OpenUrl
  49. 49.↵
    2. Li XY,
    3. Wu MY,
    4. Pan LM,
    5. Shi JL.
    Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor. Int J Nanomedicine. 2016; 11: 93–105.
    OpenUrl
  50. 50.↵
    2. Sun R,
    3. Liu Y,
    4. Li SY,
    5. Shen S,
    6. Du XJ,
    7. Xu CF, et al.
    Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials. 2015; 37: 405–14.
    OpenUrl
  51. 51.↵
    2. Maccalli C,
    3. De Maria R.
    Cancer stem cells: perspectives for therapeutic targeting. Cancer Immunol Immunother. 2015; 64: 91–7.
    OpenUrl
  52. 52.↵
    2. Borst P.
    Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2012; 2: 120066
    OpenUrlCrossRefPubMed
  53. 53.↵
    2. Van Rossum JM.
    Pharmacokinetics of accumulation. J Pharm Sci. 1968; 57: 2162–5.
    OpenUrlCrossRefPubMed
  54. 54.↵
    2. Wang Y,
    3. Liu EG,
    4. Sun XY,
    5. Huang PY,
    6. Long H,
    7. Wang H, et al.
    Pluronic L61 as a long-circulating modifier for enhanced liposomal delivery of cancer drugs. Polym Chem. 2013; 4: 2958–62.
    OpenUrl
  55. 55.↵
    2. N VR,
    3. Dinda VR,
    4. Ganivada MN,
    5. Das Sarma J,
    6. Shunmugam R.
    Efficient approach to prepare multiple chemotherapeutic agent conjugated nanocarrier. Chem Commun. 2014; 50: 13540–3.
    OpenUrl
  56. 56.
    2. Wang YP,
    3. Jiang YF,
    4. Zhang M,
    5. Tan J,
    6. Liang JM,
    7. Wang HX, et al.
    Protease-activatable hybrid nanoprobe for tumor imaging. Adv Funct Mater. 2014; 24: 5443–53.
    OpenUrl
  57. 57.↵
    2. Lammers T,
    3. Subr V,
    4. Ulbrich K,
    5. Peschke P,
    6. Huber PE,
    7. Hennink WE, et al.
    Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials. 2009; 30: 3466–75.
    OpenUrl
  58. 58.↵
    2. Szakács G,
    3. Paterson JK,
    4. Ludwig JA,
    5. Booth-Genthe C,
    6. Gottesman MM.
    Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219–34.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    2. Salehi R,
    3. Hamishehkar H,
    4. Eskandani M,
    5. Mahkam M,
    6. Davaran S.
    Development of dual responsive nanocomposite for simultaneous delivery of anticancer drugs. J Drug Target. 2014; 22: 327–42.
    OpenUrl
  60. 60.↵
    2. You YZ,
    3. Kalebaila KK,
    4. Brock SL,
    5. Oupicky D.
    Temperature- controlled uptake and release in PNIPAM-modified porous silica nanoparticles. Chem Mater. 2008; 20: 3354–9.
    OpenUrl
  61. 61.↵
    2. Feng W,
    3. Zhou XJ,
    4. He CL,
    5. Qiu KX,
    6. Nie W,
    7. Chen L, et al.
    Polyelectrolyte multilayer functionalized mesoporous silica nanoparticles for pH-responsive drug delivery: layer thickness-dependent release profiles and biocompatibility. J Mater Chem B. 2013; 1: 5886–98.
    OpenUrl
  62. 62.↵
    2. Chen JC,
    3. Liu MZ,
    4. Chen C,
    5. Gong HH,
    6. Gao CM.
    Synthesis and characterization of silica nanoparticles with well-defined thermoresponsive PNIPAM via a combination of RAFT and click chemistry. ACS Appl Mater Interfaces. 2011; 3: 3215–23.
    OpenUrlPubMed
  63. 63.↵
    2. Su TT,
    3. Long YY,
    4. Deng CY,
    5. Feng LL,
    6. Zhang XL,
    7. Chen ZB, et al.
    Construction of a two-in-one liposomal system (TWOLips) for tumor-targeted combination therapy. Int J Pharm. 2014; 476: 241–52.
    OpenUrl
  64. 64.↵
    2. Cui YN,
    3. Xu QX,
    4. Chow PKH,
    5. Wang DP,
    6. Wang CH.
    Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials. 2013; 34: 8511–20.
    OpenUrlCrossRef
  65. 65.↵
    2. Baas T.
    Finding the perfect combination. SciBX. 2012; 5: doi:10.1038/scibx.2012.832.
    OpenUrlCrossRef
  66. 66.↵
    2. Jackman AL,
    3. Kaye S,
    4. Workman P.
    The combination of cytotoxic and molecularly targeted therapies-can it be done? Drug Discov Today. 2004; 1: 445–54.
    OpenUrl
  67. 67.↵
    2. Morton SW,
    3. Lee MJ,
    4. Deng ZJ,
    5. Dreaden EC,
    6. Siouve E,
    7. Shopsowitz KE, et al.
    A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal. 2014; 7: ra44
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    2. He M,
    3. Wei MJ.
    Reversing multidrug resistance by tyrosine kinase inhibitors. Chin J Cancer. 2012; 31: 126–33.
    OpenUrlCrossRefPubMed
  69. 69.↵
    2. Wang HY,
    3. Li F,
    4. Du CG,
    5. Wang HX,
    6. Mahato RI,
    7. Huang YZ.
    Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. Mol Pharm. 2014; 11: 2600–11.
    OpenUrl
  70. 70.↵
    2. Wang JC,
    3. Goh B,
    4. Lu WL,
    5. Zhang Q,
    6. Chang A,
    7. Liu XY, et al.
    In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull. 2005; 28: 822–8.
    OpenUrlCrossRefPubMed
  71. 71.↵
    2. Qin M,
    3. Lee YEK,
    4. Ray A,
    5. Kopelman R.
    Overcoming cancer multidrug resistance by codelivery of doxorubicin and verapamil with hydrogel nanoparticles. Macromol Biosci. 2014; 14: 1106–15.
    OpenUrl
  72. 72.↵
    2. Zhao PF,
    3. Yin WM,
    4. Wu AH,
    5. Tang YS,
    6. Wang JY,
    7. Pan ZZ, et al.
    Dual-targeting to cancer cells and M2 macrophages via biomimetic delivery of mannosylated albumin nanoparticles for drug-resistant cancer therapy. Adv Funct Mater. 2017. in Press
  73. 73.↵
    2. Patel A,
    3. Patel M,
    4. Yang XY,
    5. Mitra AK.
    Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett. 2014; 21: 1102–20.
    OpenUrlCrossRef
  74. 74.
    2. Witting M,
    3. Obst K,
    4. Friess W,
    5. Hedtrich S.
    Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers. Biotechnol Adv. 2015; 33: 1355–69.
    OpenUrl
  75. 75.↵
    2. Ye ML,
    3. Kim S,
    4. Park K.
    Issues in long-term protein delivery using biodegradable microparticles. J Control Release. 2010; 146: 241–60.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    2. Adams GP,
    3. Weiner LM.
    Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005; 23: 1147–57.
    OpenUrlCrossRefPubMedWeb of Science
  77. 77.↵
    2. He Q,
    3. Gao H,
    4. Gao M,
    5. Qi SM,
    6. Zhang YQ,
    7. Wang JZ.
    Anti-gastrins antiserum combined with lowered dosage cytotoxic drugs to inhibit the growth of human gastric cancer SGC7901 cells in nude mice. J Cancer. 2015; 6: 448–56.
    OpenUrl
  78. 78.↵
    2. Slamon DJ,
    3. Leyland-Jones B,
    4. Shak S,
    5. Fuchs H,
    6. Paton V,
    7. Bajamonde A, et al.
    Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783–92.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    2. Lambert JM,
    3. Morris CQ.
    Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017; 34: 1015–35.
    OpenUrlPubMed
  80. 80.↵
    2. Beck A,
    3. Goetsch L,
    4. Dumontet C,
    5. Corvaia N.
    Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017; 16: 315–37.
    OpenUrlCrossRefPubMed
  81. 81.↵
    2. Wang SM.
    Design of small-molecule Smac mimetics as IAP antagonists//Vassilev L, Fry D. Small-molecule inhibitors of protein-protein interactions. Current Topics in Microbiology and Immunology, vol 348. Berlin: Springer, 2011:89–113.
  82. 82.↵
    2. Li MX,
    3. Liu P,
    4. Gao GH,
    5. Deng JZ,
    6. Pan ZY,
    7. Wu X, et al.
    Smac therapeutic peptide nanoparticles inducing apoptosis of cancer cells for combination chemotherapy with doxorubicin. ACS Appl Mater Interfaces. 2015; 7: 8005–12.
    OpenUrl
  83. 83.↵
    2. Sun HY,
    3. Stuckey JA,
    4. Nikolovska-Coleska Z,
    5. Qin DG,
    6. Meagher JL,
    7. Qiu S, et al.
    Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J Med Chem. 2008; 51: 7169–80.
    OpenUrlCrossRefPubMed
  84. 84.↵
    2. Mao HL,
    3. Pang YX,
    4. Zhang XL,
    5. Yang F,
    6. Zheng JF,
    7. Wang Y, et al.
    Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo. Oncol Rep. 2013; 29: 515–22.
    OpenUrlPubMed
  85. 85.↵
    2. Wang HY,
    3. Guo QQ,
    4. Jiang YF,
    5. Liu EG,
    6. Zhao YX,
    7. Wang HX, et al.
    Co-delivery of cell-permeable chimeric apoptosis AVPIR8 peptide/p53 DNA for cocktail therapy. Adv Funct Mater. 2013; 23: 6068–75.
    OpenUrl
  86. 86.↵
    2. Wang HY,
    3. Wang HX,
    4. Liang JM,
    5. Jiang YF,
    6. Guo QQ,
    7. Peng HG, et al.
    Cell-penetrating apoptotic peptide/p53 DNA nanocomplex as adjuvant therapy for drug-resistant breast cancer. Mol Pharm. 2014; 11: 3352–60.
    OpenUrl
  87. 87.↵
    2. Ezan E.
    Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev. 2013; 65: 1065–73.
    OpenUrl
  88. 88.↵
    2. Torchilin V.
    Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011; 63: 131–5.
    OpenUrlCrossRefPubMed
  89. 89.↵
    2. Roberts M,
    3. Bentley MD,
    4. Harris JM.
    Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2012; 64: 116–27.
    OpenUrl
  90. 90.↵
    2. Chen YZ,
    3. Zhang M,
    4. Jin HY,
    5. Tang YS,
    6. Wang HY,
    7. Xu Q, et al.
    Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: turning PEG dilemma into prodrug-like feature. Biomaterials. 2017; 116: 57–68.
    OpenUrl
  91. 91.↵
    2. Chen YZ,
    3. Zhang M,
    4. Jin HY,
    5. Tang YS,
    6. Wu AH,
    7. Xu Q, et al.
    Prodrug-like, PEGylated protein toxin trichosanthin for reversal of chemoresistance. Mol Pharm. 2017; 14: 1429–38.
    OpenUrl
  92. 92.↵
    2. Dancey JE,
    3. Bedard PL,
    4. Onetto N,
    5. Hudson TJ.
    The genetic basis for cancer treatment decisions. Cell. 2012; 148: 409–20.
    OpenUrlCrossRefPubMedWeb of Science
  93. 93.↵
    2. Alexander S,
    3. Friedl P.
    Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol Med. 2012; 18: 13–26.
    OpenUrlCrossRefPubMed
  94. 94.↵
    2. Pecot CV,
    3. Calin GA,
    4. Coleman RL,
    5. Lopez-Berestein G,
    6. Sood AK.
    RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011; 11: 59–67.
    OpenUrlCrossRefPubMedWeb of Science
  95. 95.↵
    2. Yin Q,
    3. Shen JA,
    4. Chen LL,
    5. Zhang ZW,
    6. Gu WW,
    7. Li YP.
    Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(Î2-amino esters). Biomaterials. 2012; 33: 6495–506.
    OpenUrl
  96. 96.↵
    2. Bai L,
    3. Zhu WG.
    p53: structure, function and therapeutic applications. J Cancer Mol. 2006; 2: 141–53.
    OpenUrl
  97. 97.↵
    2. Wiradharma N,
    3. Tong YW,
    4. Yang YY.
    Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials. 2009; 30: 3100–9.
    OpenUrlCrossRefPubMed
  98. 98.↵
    2. Zhao F,
    3. Yin H,
    4. Li J.
    Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug. Biomaterials. 2014; 35: 1050–62.
    OpenUrl
  99. 99.↵
    2. Qi XD,
    3. Chang ZK,
    4. Song J,
    5. Gao G,
    6. Shen Z.
    Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Anticancer Drugs. 2011; 22: 556–62.
    OpenUrlCrossRefPubMed
  100. 100.↵
    2. Chen AM,
    3. Zhang M,
    4. Wei DG,
    5. Stueber D,
    6. Taratula O,
    7. Minko T, et al.
    Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009; 5: 2673–7.
    OpenUrlCrossRefPubMedWeb of Science
  101. 101.↵
    2. Zou SY,
    3. Cao N,
    4. Cheng D,
    5. Zheng RQ,
    6. Wang J,
    7. Zhu KS, et al.
    Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin. Int J Nanomedicine. 2012; 7: 3823–35.
    OpenUrlPubMed
  102. 102.↵
    2. Zhang CG,
    3. Zhu WJ,
    4. Liu Y,
    5. Yuan ZQ,
    6. Yang SD,
    7. Chen WL, et al.
    Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy. Sci Rep. 2016; 6: 23859
    OpenUrl
  103. 103.↵
    2. Xiong XB,
    3. Lavasanifar A.
    Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. 2011; 5: 5202–13.
    OpenUrlCrossRefPubMedWeb of Science
  104. 104.↵
    2. Patil YB,
    3. Swaminathan SK,
    4. Sadhukha T,
    5. Ma LA,
    6. Panyam J.
    The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2010; 31: 358–65.
    OpenUrlCrossRefPubMed
  105. 105.↵
    2. Han M,
    3. Lv Q,
    4. Tang XJ,
    5. Hu YL,
    6. Xu DH,
    7. Li FZ, et al.
    Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Release. 2012; 163: 136–44.
    OpenUrlCrossRefPubMed
  106. 106.↵
    2. Tu SP,
    3. Jiang XH,
    4. Lin MC,
    5. Cui JT,
    6. Yang Y,
    7. Lum CT, et al.
    Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003; 63: 7724–32.
    OpenUrlAbstract/FREE Full Text
  107. 107.↵
    2. Hu QL,
    3. Li W,
    4. Hu XR,
    5. Hu QD,
    6. Shen J,
    7. Jin X, et al.
    Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. Biomaterials. 2012; 33: 6580–91.
    OpenUrlCrossRefPubMed
  108. 108.↵
    2. Salzano G,
    3. Riehle R,
    4. Navarro G,
    5. Perche F,
    6. De Rosa G,
    7. Torchilin VP.
    Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer. Cancer Lett. 2014; 343: 224–31.
    OpenUrlCrossRefPubMed
  109. 109.↵
    2. Qin XC,
    3. Guo ZY,
    4. Liu ZM,
    5. Zhang W,
    6. Wan MM,
    7. Yang BW.
    Folic acid-conjugated graphene oxide for cancer targeted chemo- photothermal therapy. J Photochem Photobiol B. 2013; 120: 156–62.
    OpenUrl
  110. 110.↵
    2. Bai J,
    3. Liu Y,
    4. Jiang XE.
    Multifunctional PEG-GO/CuS nanocomposites for near-infrared chemo-photothermal therapy. Biomaterials. 2014; 35: 5805–13.
    OpenUrl
  111. 111.↵
    2. Xu JJ,
    3. Xu BH,
    4. Tao J,
    5. Yang YX,
    6. Hu Y,
    7. Huang YZ.
    Microneedle-assisted, DC-targeted codelivery of pTRP-2 and adjuvant of paclitaxel for transcutaneous immunotherapy. Small. 2017, doi: 10.1002/smll.201700666. in press
    OpenUrlCrossRef
  112. 112.↵
    2. Tao Y,
    3. Ju EG,
    4. Liu Z,
    5. Dong K,
    6. Ren JS,
    7. Qu XG.
    Engineered, self-assembled near-infrared photothermal agents for combined tumor immunotherapy and chemo-photothermal therapy. Biomaterials. 2014; 35: 6646–56.
    OpenUrl
  113. 113.↵
    2. Hainfeld JF,
    3. Slatkin DN,
    4. Smilowitz HM.
    The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004; 49: N309–15.
    OpenUrlCrossRefPubMedWeb of Science
  114. 114.
    2. Mesbahi A.
    A review on gold nanoparticles radiosensitization effect in radiation therapy of cancer. Rep Pract Oncol Radiother. 2010; 15: 176–80.
    OpenUrl
  115. 115.↵
    2. Park J,
    3. Park J,
    4. Ju EJ,
    5. Park SS,
    6. Choi J,
    7. Lee JH, et al.
    Multifunctional hollow gold nanoparticles designed for triple combination therapy and CT imaging. J Control Release. 2015; 207: 77–85.
    OpenUrl
  116. 116.↵
    2. Ostad SN,
    3. Dehnad S,
    4. Nazari ZE,
    5. Fini ST,
    6. Mokhtari N,
    7. Shakibaie M, et al.
    Cytotoxic activities of silver nanoparticles and silver ions in parent and tamoxifen-resistant T47D human breast cancer cells and their combination effects with tamoxifen against resistant cells. Avicenna J Med Biotechnol. 2010; 2: 187–96.
    OpenUrl
  117. 117.↵
    2. Milane L,
    3. Duan ZF,
    4. Amiji M.
    Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine. 2011; 7: 435–44.
    OpenUrlCrossRefPubMed
  118. 118.↵
    2. Lee BK,
    3. Yun YH,
    4. Park K.
    Smart nanoparticles for drug delivery: boundaries and opportunities. Chem Eng Sci. 2015; 125: 158–64.
    OpenUrl
  119. 119.↵
    2. Villanueva MT.
    Therapeutic resistance: paradox breaking. Nat Rev Cancer. 2015; 15: 71
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords